SEC Form 4 · accession 0001209191-17-046040
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sujal Shah
Officer — Interim President & CEO · Director
Period of report
Jul 20, 2017
Accepted (ET)
Jul 24, 2017 · 6:15 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 20, 2017 | P | 891 | $7.29 | A | 75,891 | D | |
| Common Stock | Jul 20, 2017 | P | 400 | $7.30 | A | 76,291 | D | |
| Common Stock | Jul 20, 2017 | P | 576 | $7.31 | A | 76,867 | D | |
| Common Stock | Jul 20, 2017 | P | 100 | $7.32 | A | 76,967 | D | |
| Common Stock | Jul 20, 2017 | P | 8,033 | $7.35 | A | 85,000 | D |
Table II — derivative securities
No Table II lines on this filing.